IR@PKUHSC  > 北京大学第三临床医学院
学科主题临床医学
A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation
Lin, San-Ren1; Ke, Mei-Yun1; Luo, Jin-Yan1; Yuan, Yao-Zong1; Wang, Ji-Yao1; diTommaso, Shelley1; Walter, Verena1; Huang, Jiaqing1
关键词Chronic Constipation Tegaserod China Complete Spontaneous Bowel Movement Placebo-controlled Stool
刊名WORLD JOURNAL OF GASTROENTEROLOGY
2007-02-07
13期:5页:732-739
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Gastroenterology & Hepatology
研究领域[WOS]Gastroenterology & Hepatology
关键词[WOS]IRRITABLE-BOWEL-SYNDROME ; MANAGEMENT ; SYMPTOMS ; TRANSIT
英文摘要

AIM: To evaluate the efficacy and safety of tegaserod, 6 mg twice daily (b.i.d..), in men and women with chronic constipation (CC) from China.

METHODS: This was a multicenter, double-blind, placebo-controlled study. Following a 2-wk treatmentfree baseline period, patients were randomized to receive either tegaserod (6 mg b.i.d.) or placebo (b.i.d.) for 4 wk. An analysis of covariance with repeated measures was used to determine the overall effect of treatment for the primary efficacy variable; the change from baseline in the number of complete spontaneous bowel movements (CSBMs) during the 4-wk treatment period. Secondary efficacy endpoints included other measures of response in terms of CSBMs, and patients′ daily and weekly assessment of bowel habits. Safety was also assessed, based on the incidence and severity of adverse events (AEs).

RESULTS: A total of 607 patients were randomized to receive either tegaserod (n = 304) or placebo (n = 303). Tegaserod treatment resulted in a rapid and significant increase from baseline in the adjusted mean, number of CSBMs per week over wk 1-4 compared with placebo (1.39 vs 0.91, P = 0.0002). A statistically significant difference in favor of tegaserod was also observed for a mean increase >= 1 CSBM/wk over wk 1-4 (47.7% vs 35.0%, tegaserod vs placebo, respectively, P = 0.0018) and for the absolute number of >= 3 CSBMs/wk over wk 1-4 (25.0% vs 14.5%, tegaserod vs placebo, respectively, P = 0.0021). Improvements in other symptoms of CC were also seen in the tegaserod group, including improved stool form and reduced straining. In addition, more patients in the tegaserod group reported satisfactory relief from their constipation symptoms. The frequency and severity of AEs was comparable between tegaserod and placebo groups, with the exception of a greater incidence of diarrhea in patients receiving tegaserod (3.6%) compared with placebo (1.7%).

CONCLUSION: Tegaserod treatment improved multiple symptoms of CC and was associated with a favorable safety profile. (c) 2007 The WJG Press. All rights reserved.

语种英语
WOS记录号WOS:000244087400010
引用统计
被引频次:7[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/52097
专题北京大学第三临床医学院
作者单位1.Shanghai Zhongshan Hosp, Shanghai, Peoples R China
2.Novartis Pharma AG, Basel, Switzerland
3.Shanghai Ruijin Hosp, Shanghai, Peoples R China
4.Beijing Med Univ, Hosp 3, Beijing 100083, Peoples R China
5.Xian Jiaotong Univ, Hosp 2, Shanxi, Peoples R China
6.Novartis Pharmaceut Corp, Gastroenterol Urol Therapeut Area, Clin Dev & Med Affairs, E Hanover, NJ 07936 USA
7.Beijing Union Med Coll Hosp, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Lin, San-Ren,Ke, Mei-Yun,Luo, Jin-Yan,et al. A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation[J]. WORLD JOURNAL OF GASTROENTEROLOGY,2007,13(5):732-739.
APA Lin, San-Ren.,Ke, Mei-Yun.,Luo, Jin-Yan.,Yuan, Yao-Zong.,Wang, Ji-Yao.,...&Huang, Jiaqing.(2007).A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation.WORLD JOURNAL OF GASTROENTEROLOGY,13(5),732-739.
MLA Lin, San-Ren,et al."A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation".WORLD JOURNAL OF GASTROENTEROLOGY 13.5(2007):732-739.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Lin, San-Ren]的文章
[Ke, Mei-Yun]的文章
[Luo, Jin-Yan]的文章
百度学术
百度学术中相似的文章
[Lin, San-Ren]的文章
[Ke, Mei-Yun]的文章
[Luo, Jin-Yan]的文章
必应学术
必应学术中相似的文章
[Lin, San-Ren]的文章
[Ke, Mei-Yun]的文章
[Luo, Jin-Yan]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。